0PB Stock Chart & Stats
€5.05
€0.00(0.00%)
At close: 4:00 PM EDT
€5.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.03 - €5.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€475.56M
Enterprise Value€337.47M
Total Cash (Recent Filing)€93.90M
Total Debt (Recent Filing)€4.82M
Price to Earnings (P/E)19.2
Beta0.92
Next Earnings
Oct 29, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.54
Shares Outstanding51,620,068
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.28
Price to Sales (P/S)1.30
P/FCF Ratio7.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.35Price Target Upside5.96% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.33
Revenue Forecast (FY)€193.37M
Bulls Say, Bears Say
Bulls Say
Raised Revenue And Income GuidanceHigher full-year revenue and net income guidance indicates management sees improving commercial execution and earnings visibility. If achieved, the stronger outlook should support continued investment in oncology development while reinforcing confidence in NERLYNX’s ability to generate operating profit.
Debt-Free Balance SheetDebt elimination materially improves financial flexibility by removing principal and interest obligations from future cash planning. The cash and securities balance provides a stronger base for funding clinical programs, commercial operations, and other strategic priorities without relying on new borrowing.
Oncology Pipeline ExpansionActive Phase 2 development gives Puma potential to broaden its oncology portfolio beyond its marketed therapy. Continued enrollment and planned additional studies can create future growth opportunities and diversify the company’s long-term commercial base if clinical objectives are met.
Bears Say
High Gross-to-Net DeductionsLarge gross-to-net deductions reduce the revenue Puma retains from reported NERLYNX demand, limiting the conversion of prescription and bottle growth into net sales. A persistently high Medicaid mix could keep realized revenue and margins under pressure across coming quarters.
China Royalty Reduction RiskA generic-triggered reduction in the China sublicense royalty rate could lower a recurring source of product-related economics. The risk is structural rather than temporary, and would reduce international contribution at a time when Puma is developing additional clinical programs.
Higher R&D Spending And Cash BurnAccelerating R&D investment can advance Puma’s clinical pipeline, but it also raises the cash required before new programs generate returns. The higher quarterly burn may reduce the duration of the current cash cushion and increase dependence on NERLYNX operating performance.
Puma Biotechnology News
0PB FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was €4.03 and its highest was €5.20 in the past 12 months.
What is Puma Biotechnology’s market cap?
Puma Biotechnology’s market cap is €475.56M.
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Oct 29, 2026 which is in 16 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on Aug 06, 2026. The company reported €0.143 earnings per share for the quarter, beating the consensus estimate of €0.036 by €0.107.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Undervalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is 0.08.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 51,620,068 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of €0.143 in its last earnings report, beating expectations of €0.036. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Currently, no hedge funds are holding shares in DE:0PB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Puma Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€5.35 (5.96% Upside)
€5.35 (5.96% Upside)
Blogger Sentiment
Neutral
DE:0PB Sentiment 50%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.97%
12-Months-Change
Fundamentals
Return on Equity
20.85%
Trailing 12-Months
Asset Growth
-1.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
0PB Company Deck
0PB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum: meaningful QoQ and YoY increases in NERLYNX demand and bottle sales, a return to GAAP profitability in Q2, raised full-year revenue and net income guidance, and elimination of debt. These positives are tempered by pressure from high gross-to-net deductions (~28%), potential royalty reductions in China when generics gain share, rising R&D spend and increased quarter-over-quarter cash burn, and operational items like elevated DSO and a QoQ decline in new patient starts. On balance, the company appears to be in a strengthening commercial and financial position while managing identifiable near-term risks tied to deductions, international royalties, and increased investment in clinical programs.View all DE:0PB earnings summaries0PB Stock 12 Month Forecast
Average Price Target
€5.35
▲(5.96% Upside)
Technical Analysis
Heron Therapeutics
―
Voyager Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―